Engineered liposomal nanoparticles have unique characteristics as cargo carriers in cancer
care and therapeutics. Liposomal theranostics have shown significant progress in preclinical …

Leukemia is a widespread hematological malignancy characterized by an elevated white
blood cell count in both the blood and the bone marrow. Despite notable advancements in …

High-risk neuroblastoma has poor survival due to treatment failure and off-target side effects
of therapy. Small molecule inhibitors have shown therapeutic efficacy at targeting oncogenic …

We created valrubicin-loaded immunoliposomes (Val-ILs) using the antitumor prodrug
valrubicin, a hydrophobic analog of daunorubicin. Being lipophilic, valrubicin readily …

Background: Leukemia, a cancer impacting blood-forming tissues such as bone marrow and
the lymphatic system, presents in various forms, affecting children and adults differently. The …

Introduction Despite improvements in chemotherapy and molecularly targeted therapies, the
life expectancy of patients with advanced non-small cell lung cancer (NSCLC) remains less …

Antibody-directed targeting of chemotherapeutic nanomaterials to primary human cancers
could improve efficacy and reduce off-target toxicities. We developed an ex vivo model to …

Glycosidic switch liposome (GSL) technology uses a reversible glucuronide ester to
efficiently encapsulate and stably retain potent anticancer drugs in liposomes. Parental drug …

High-risk neuroblastoma is an aggressive childhood cancer, for which 5-year survival
remains less than 50%. Current therapies are non-specific and can lead to acute and long …